Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Puma Biotechnology (PBYI) over the last 8 years, with Q3 2025 value amounting to -$11.3 million.

  • Puma Biotechnology's Cash from Financing Activities fell 133.24% to -$11.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$45.2 million, marking a year-over-year decrease of 10074.17%. This contributed to the annual value of -$33.8 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Puma Biotechnology reported Cash from Financing Activities of -$11.3 million as of Q3 2025, which was down 133.24% from -$11.2 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Cash from Financing Activities high stood at $9.8 million for Q1 2022, and its period low was -$31.9 million during Q3 2021.
  • Moreover, its 4-year median value for Cash from Financing Activities was -$11.2 million (2025), whereas its average is -$7.9 million.
  • Per our database at Business Quant, Puma Biotechnology's Cash from Financing Activities tumbled by 7435348.84% in 2021 and then surged by 12165000.0% in 2022.
  • Quarter analysis of 4 years shows Puma Biotechnology's Cash from Financing Activities stood at -$2000.0 in 2021, then skyrocketed by 121650.0% to $2.4 million in 2022, then crashed by 566.1% to -$11.3 million in 2024, then decreased by 0.01% to -$11.3 million in 2025.
  • Its last three reported values are -$11.3 million in Q3 2025, -$11.2 million for Q2 2025, and -$11.3 million during Q1 2025.